Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Apar Kishor Ganti(Susan Thompson Buffett Foundation), Billy W. Loo(Cancer Institute (WIA)), M. Bassetti(University of Wisconsin Carbone Cancer Center), Collin M. Blakely(UCSF Helen Diller Family Comprehensive Cancer Center), Anne C. Chiang(Smilow Cancer Hospital), Thomas A. D’Amico(Cancer Institute (WIA)), Christopher D’Avella(University of Pennsylvania), Afshin Dowlati(Cleveland Clinic), Robert J. Downey(Fox Chase Cancer Center), Martin J. Edelman(Fox Chase Cancer Center), Charles Florsheim, Kathryn A. Gold(University of California San Diego), Jonathan W. Goldman(University of Colorado Cancer Center), J.C. Grecula(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Christine L. Hann(Sidney Kimmel Comprehensive Cancer Center), Wade T. Iams(Breast Cancer Research Foundation), Puneeth Iyengar(Southwestern Medical Center), Karen Kelly(UC Davis Comprehensive Cancer Center), Maya Khalil(University of Colorado Cancer Center), Marianna Koczywas(City Of Hope National Medical Center), Robert E. Merritt(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nisha Mohindra(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Julian R. Molina, César A. Moran(The University of Texas MD Anderson Cancer Center), Saraswati Pokharel, Sonam Puri(University of Utah), Angel Qin(University of Michigan), Chad G. Rusthoven(University of Colorado Cancer Center), Jacob Sands(Dana-Farber Brigham Cancer Center), Rafael Santana-Dávila(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael Shafique(Moffitt Cancer Center), Saiama N. Waqar(Barnes-Jewish Hospital), Kristina M. Gregory(Pancreatic Cancer Action Network), Miranda Hughes(Pancreatic Cancer Action Network)
Journal of the National Comprehensive Cancer Network
December 1, 2021
Cited by 457Open Access
Full Text

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.


Related Papers

No related papers found

Powered by citation graph analysis